Computational	O
analysis	O
and	O
predictive	O
modeling	O
of	O
polymorph	O
descriptors	O

Background	O

A	O
computation	O
approach	O
based	O
on	O
integrating	O
high	O
throughput	O
binding	O
affinity	O
comparison	O
and	O
binding	O
descriptor	O
classifications	O
was	O
utilized	O
to	O
establish	O
the	O
correlation	O
among	O
substrate	O
properties	O
and	O
their	O
affinity	O
to	O
Breast	B-GP
Cancer	I-GP
Resistant	I-GP
Protein	I-GP
(	O
BCRP	B-GP
).	O

The	O
uptake	O
rates	O
of	O
Mitoxantrone	O
in	O
the	O
presence	O
of	O
various	O
substrates	O
were	O
evaluated	O
as	O
an	O
in	O
vitro	O
screening	O
index	O
for	O
comparison	O
of	O
their	O
binding	O
affinity	O
to	O
BCRP	B-GP
.	O

The	O
effects	O
of	O
chemical	O
properties	O
of	O
various	O
chemotherapeutics	O
,	O
such	O
as	O
antiviral	O
,	O
antibiotic	O
,	O
calcium	B-GP
channel	I-GP
blockers	O
,	O
anticancer	O
and	O
antifungal	O
agents	O
,	O
on	O
their	O
affinity	O
to	O
BCRP	B-GP
,	O
were	O
evaluated	O
using	O
HEK	O
(	O
human	B-OG
embryonic	O
kidney	O
)	O
cells	O
in	O
which	O
3	O
polymorphs	O
,	O
namely	O
482R	O
(	O
wild	O
type	O
)	O
and	O
two	O
mutants	O
(	O
482G	O
and	O
482T	O
)	O
of	O
BCRP	B-GP
,	O
have	O
been	O
identified	O
.	O

The	O
quantitative	O
structure	O
activity	O
relationship	O
(	O
QSAR	O
)	O
model	O
was	O
developed	O
using	O
the	O
sequential	O
approaches	O
of	O
Austin	O
Model	O
1	O
(	O
AM1	O
),	O
CODESSA	O
program	O
,	O
heuristic	O
method	O
(	O
HM	O
)	O
and	O
multiple	O
linear	O
regression	O
(	O
MLR	O
)	O
to	O
establish	O
the	O
relationship	O
between	O
structural	O
specificity	O
of	O
BCRP	B-GP
substrates	O
and	O
their	O
uptake	O
rates	O
by	O
BCRP	B-GP
polymorphs	O
.	O

Results	O

The	O
BCRP	B-GP
mutations	O
may	O
induce	O
conformational	O
changes	O
as	O
manifested	O
by	O
the	O
altered	O
uptake	O
rates	O
of	O
Mitoxantrone	O
by	O
BCRP	B-GP
in	O
the	O
presence	O
of	O
other	O
competitive	O
binding	O
substrates	O
that	O
have	O
a	O
varying	O
degree	O
of	O
affinities	O
toward	O
BCRP	B-GP
efflux	O
.	O

This	O
study	O
also	O
revealed	O
that	O
the	O
binding	O
affinity	O
of	O
test	O
substrates	O
to	O
each	O
polymorph	O
was	O
affected	O
by	O
varying	O
descriptors	O
,	O
such	O
as	O
constitutional	O
,	O
topological	O
,	O
geometrical	O
,	O
electrostatic	O
,	O
thermodynamic	O
,	O
and	O
quantum	O
chemical	O
descriptors	O
.	O

Conclusion	O

Descriptors	O
involved	O
with	O
the	O
net	O
surface	O
charge	O
and	O
energy	O
level	O
of	O
substrates	O
seem	O
to	O
be	O
the	O
common	O
integral	O
factors	O
for	O
defining	O
binding	O
specificity	O
of	O
selected	O
substrates	O
to	O
BCRP	B-GP
polymorph	O
.	O

The	O
reproducible	O
outcomes	O
and	O
validation	O
process	O
further	O
supported	O
the	O
accuracy	O
of	O
the	O
computational	O
model	O
in	O
assessing	O
the	O
correlation	O
among	O
descriptors	O
involved	O
with	O
substrate	O
affinity	O
to	O
BCRP	B-GP
polymorph	O
.	O

A	O
quantitative	O
computation	O
approach	O
will	O
provide	O
important	O
structural	O
insight	O
into	O
optimal	O
designing	O
of	O
new	O
chemotherapeutic	O
agents	O
with	O
improved	O
pharmacological	O
efficacies	O
.	O

Background	O

The	O
computational	O
tools	O
intended	O
for	O
quantitative	O
assessment	O
of	O
protein	O
-	O
ligand	O
interactions	O
are	O
based	O
on	O
several	O
factors	O
including	O
protein	O
-	O
ligand	O
docking	O
,	O
molecular	O
dynamic	O
simulation	O
and	O
free	O
energy	O
calculations	O
[	O
1	O
].	O

To	O
better	O
define	O
the	O
role	O
of	O
binding	O
affinity	O
in	O
forming	O
a	O
protein	O
-	O
ligand	O
complex	O
,	O
a	O
structural	O
characterization	O
for	O
putative	O
human	B-OG
off	O
-	O
targets	O
was	O
recently	O
performed	O
on	O
Nelfinavir	O
,	O
a	O
potent	O
HIV	B-OG
-	O
protease	B-GP
inhibitor	O
with	O
pleiotropic	O
effects	O
in	O
cancer	B-DS
cells	O
[	O
2	O
].	O

In	O
this	O
experiment	O
,	O
they	O
have	O
adapted	O
numerous	O
computational	O
models	O
that	O
integrated	O
molecular	O
dynamic	O
simulation	O
,	O
free	O
energy	O
calculations	O
with	O
ligand	O
binding	O
site	O
comparison	O
and	O
biological	O
network	O
analysis	O
.	O

There	O
are	O
two	O
integral	O
screening	O
approaches	O
that	O
could	O
help	O
identify	O
and	O
characterize	O
the	O
substrates	O
and	O
inhibitors	O
of	O
the	O
efflux	B-GP
proteins	I-GP
and	O
/	O
or	O
transporter	B-GP
system	O
;	O
the	O
measurement	O
of	O
binding	O
affinity	O
and	O
toxicity	O
analysis	O
of	O
substrate	O
compounds	O
[	O
3	O
].	O

There	O
was	O
a	O
report	O
that	O
drug	O
resident	O
time	O
and	O
uptake	O
amount	O
are	O
better	O
correlated	O
with	O
drug	O
efficacy	O
than	O
the	O
binding	O
affinity	O
[	O
4	O
-	O
6	O
],	O
suggesting	O
that	O
lead	O
optimization	O
could	O
be	O
efficiently	O
accomplished	O
with	O
analyzing	O
the	O
drug	O
uptake	O
profiles	O
.	O

Although	O
numerous	O
methodologies	O
have	O
been	O
proposed	O
for	O
drug	O
-	O
target	O
screening	O
strategies	O
based	O
on	O
binding	O
affinity	O
[	O
7	O
,	O
8	O
],	O
there	O
are	O
no	O
efficient	O
computational	O
tools	O
available	O
for	O
the	O
accurate	O
estimation	O
of	O
the	O
drug	O
uptake	O
profiles	O
from	O
the	O
point	O
of	O
the	O
molecular	O
structures	O
.	O

In	O
this	O
study	O
,	O
the	O
uptake	O
rates	O
of	O
Mitoxantrone	O
in	O
the	O
presence	O
of	O
various	O
substrate	O
compounds	O
were	O
examined	O
as	O
an	O
in	O
vitro	O
screening	O
index	O
that	O
could	O
help	O
to	O
characterize	O
the	O
binding	O
properties	O
of	O
chemotherapeutic	O
drugs	O
to	O
tumor	B-DS
cells	O
or	O
efflux	B-GP
proteins	I-GP
.	O

Breast	B-GP
cancer	I-GP
resistant	I-GP
protein	I-GP
(	O
BCRP	B-GP
)	O
also	O
known	O
as	O
ABCP	B-GP
or	O
MXR	B-GP
or	O
ABCG2	B-GP
is	O
a	O
member	O
of	O
transporter	B-GP
super	O
family	O
ATP	B-GP
binding	I-GP
cassette	I-GP
(	O
ABC	B-GP
)	O
proteins	O
.	O

BCRP	B-GP
is	O
known	O
to	O
affect	O
the	O
therapeutically	O
available	O
concentrations	O
of	O
various	O
clinical	O
agents	O
[	O
9	O
-	O
11	O
].	O

Since	O
the	O
BCRP	B-GP
effluxes	O
a	O
wide	O
range	O
of	O
structurally	O
diverse	O
xenobiotic	O
compounds	O
from	O
cells	O
[	O
12	O
],	O
the	O
broad	O
distribution	O
of	O
BCRP	B-GP
not	O
only	O
renders	O
less	O
complete	O
distribution	O
of	O
drugs	O
but	O
also	O
causes	O
a	O
poor	O
response	O
of	O
cells	O
to	O
chemotherapeutics	O
[	O
13	O
-	O
15	O
].	O

BCRP	B-GP
in	O
conjunction	O
with	O
P	B-GP
-	I-GP
gp	I-GP
expression	O
at	O
target	O
sites	O
affected	O
the	O
pharmacokinetic	O
profiles	O
of	O
substrates	O
and	O
inhibitors	O
[	O
16	O
].	O

Subsequently	O
,	O
the	O
therapeutically	O
available	O
concentrations	O
of	O
certain	O
agents	O
increased	O
in	O
BCRP	B-GP
knock	O
-	O
out	O
animal	B-OG
models	O
that	O
were	O
highly	O
prone	O
to	O
Mitoxantrone	O
induced	O
toxicity	O
[	O
17	O
].	O

The	O
in	O
vitro	O
studies	O
on	O
the	O
BCRP	B-GP
efflux	O
system	O
have	O
demonstrated	O
that	O
some	O
cell	O
lines	O
displayed	O
erratic	O
efflux	O
profiles	O
of	O
doxorubicin	O
and	O
rhodamine	O
123	O
,	O
and	O
these	O
observations	O
were	O
attributable	O
to	O
482nd	O
position	O
in	O
the	O
amino	O
acid	O
sequence	O
consisting	O
of	O
arginine	O
,	O
glycine	O
or	O
threonine	O
residues	O
which	O
are	O
susceptible	O
to	O
numerous	O
posttranslational	O
modifications	O
[	O
18	O
-	O
20	O
].	O

Three	O
polymorphs	O
,	O
namely	O
482R	O
(	O
wild	O
type	O
)	O
and	O
two	O
mutants	O
(	O
482G	O
and	O
482T	O
)	O
of	O
BCRP	B-GP
,	O
have	O
been	O
identified	O
,	O
and	O
alterations	O
in	O
their	O
expressions	O
and	O
functions	O
were	O
reported	O
[	O
21	O
].	O

Wild	O
-	O
type	O
BCRP	B-GP
and	O
its	O
variants	O
were	O
markedly	O
expressed	O
in	O
human	B-OG
embryonic	O
kidney	O
(	O
HEK	O
)	O
cells	O
[	O
22	O
].	O

The	O
present	O
study	O
was	O
intended	O
to	O
establish	O
the	O
relationships	O
between	O
chemical	O
properties	O
involved	O
with	O
the	O
uptake	O
rates	O
of	O
structurally	O
diverse	O
substrates	O
and	O
BCRP	B-GP
polymorphs	O
.	O

To	O
achieve	O
this	O
goal	O
,	O
we	O
have	O
designed	O
the	O
computational	O
model	O
consisting	O
of	O
numerous	O
molecular	O
descriptors	O
.	O

The	O
uptake	O
rates	O
of	O
Mitoxantrone	O
by	O
BCRP	B-GP
were	O
examined	O
in	O
the	O
presence	O
of	O
various	O
pharmacological	O
classes	O
of	O
ABC	B-GP
transporter	I-GP
inhibitors	O
,	O
such	O
as	O
antiviral	O
(	O
i	O
.	O
e	O
.	O
Erythromycin	O
,	O
Foscarnet	O
),	O
antibiotic	O
(	O
i	O
.	O
e	O
.	O
Ciprofloxacin	O
,	O
Febendazole	O
,	O
Novobiocin	O
,	O
Quercitin	O
),	O
calcium	B-GP
channel	I-GP
blockers	O
(	O
i	O
.	O
e	O
.	O
Verapamil	O
,	O
Diltiazem	O
,	O
Nifedipine	O
,	O
Qunidine	O
),	O
anticancer	O
(	O
i	O
.	O
e	O
.	O
Mitroxantrone	O
,	O
Acyclovir	O
,	O
FTC	O
,	O
Phenethyl	O
ITC	O
,	O
Raloxifene	O
,	O
Rodamin	O
123	O
,	O
Saquinavir	O
,	O
Tamoxifene	O
),	O
antifungal	O
agents	O
(	O
i	O
.	O
e	O
.	O
Ketoconazole	O
),	O
hormones	B-GP
(	O
i	O
.	O
e	O
.,	O
Estradiol	O
)	O
and	O
immunosuppressant	O
(	O
Cyclosporin	O
)	O
[	O
16	O
,	O
23	O
].	O

It	O
was	O
hypothesized	O
that	O
any	O
changes	O
in	O
uptake	O
rates	O
of	O
Mitoxantrone	O
are	O
due	O
to	O
competitive	O
binding	O
of	O
these	O
substrates	O
to	O
BCRP	B-GP
.	O

In	O
the	O
development	O
of	O
a	O
computational	O
model	O
for	O
prediction	O
of	O
structural	O
specificity	O
of	O
substrate	O
compounds	O
to	O
BCRP	B-GP
,	O
three	O
dimensional	O
structures	O
of	O
the	O
substrates	O
were	O
built	O
using	O
AMPAC	O
with	O
Graphical	O
User	O
Interface	O
(	O
Semichem	O
,	O
Shawnee	O
Mission	O
,	O
KS	O
).	O

AMPAC	O
used	O
Austin	O
Model	O
1	O
(	O
AM1	O
)	O
for	O
the	O
quantum	O
mechanical	O
semi	O
-	O
empirical	O
calculations	O
of	O
interactive	O
energy	O
.	O

CODESSA	O
can	O
generate	O
the	O
numerical	O
values	O
for	O
molecular	O
descriptors	O
,	O
whereas	O
the	O
heuristic	O
method	O
(	O
HM	O
)	O
preselects	O
appropriate	O
molecular	O
descriptors	O
.	O

The	O
multiple	O
linear	O
regression	O
(	O
MLR	O
)	O
is	O
capable	O
of	O
deriving	O
the	O
linear	O
QSAR	O
based	O
on	O
them	O
.	O

The	O
final	O
outcomes	O
were	O
labeled	O
as	O
a	O
characterization	O
of	O
compounds	O
using	O
derived	O
properties	O
X	O
from	O
AM1	O
calculations	O
and	O
regression	O
with	O
MLR	O
,	O
using	O
measurements	O
Y	O
as	O
response	O
.	O

The	O
knowledge	O
on	O
such	O
descriptors	O
that	O
determine	O
substrate	O
specificity	O
to	O
binding	O
receptors	O
is	O
critical	O
to	O
delineate	O
the	O
drug	O
interaction	O
with	O
BCRP	B-GP
polymorphs	O
and	O
the	O
mechanisms	O
behind	O
their	O
action	O
.	O

The	O
outcomes	O
of	O
this	O
study	O
ultimately	O
lead	O
us	O
to	O
discover	O
efficient	O
new	O
drugs	O
with	O
enhanced	O
chemotherapeutic	O
efficacies	O
.	O

Results	O
and	O
discussion	O

The	O
uptake	O
rates	O
of	O
Mitoxantrone	O
by	O
HEK	O
cells	O

The	O
effects	O
of	O
various	O
substrates	O
on	O
the	O
uptake	O
rates	O
of	O
Mitoxantrone	O
by	O
HEK	O
cells	O
were	O
evaluated	O
to	O
determine	O
their	O
binding	O
capacity	O
to	O
BCRP	B-GP
polymorphs	O
.	O

The	O
uptake	O
rates	O
of	O
Mitoxantrone	O
(	O
expressed	O
per	O
mg	O
of	O
protein	O
)	O
in	O
the	O
presence	O
of	O
various	O
substrates	O
were	O
converted	O
to	O
the	O
percentage	O
uptake	O
rate	O
of	O
Mitoxantrone	O
in	O
the	O
absence	O
of	O
the	O
substrates	O
(	O
Figure	O
1	O
).	O

The	O
transcellular	O
permeation	O
profiles	O
of	O
the	O
substrate	O
compounds	O
showed	O
a	O
similar	O
trend	O
to	O
those	O
of	O
the	O
uptake	O
profiles	O
,	O
but	O
statistical	O
significance	O
of	O
the	O
latter	O
is	O
much	O
greater	O
than	O
the	O
former	O
.	O

There	O
are	O
several	O
important	O
findings	O
from	O
this	O
study	O
.	O

1	O
.	O

Estrogen	O
and	O
tamoxifen	O
did	O
not	O
significantly	O
affect	O
the	O
Mitoxantrone	O
uptake	O
profiles	O
,	O
which	O
are	O
consistent	O
with	O
the	O
previous	O
findings	O
[	O
24	O
].	O

2	O
.	O

Substrate	O
compounds	O
,	O
such	O
as	O
Ciprofloxacin	O
,	O
Ketoconazole	O
and	O
Verapamil	O
,	O
allow	O
for	O
a	O
greater	O
Mitoxantrone	O
uptake	O
rate	O
in	O
482G	O
than	O
482R	O
.	O

BCRP	B-GP
substrates	O
with	O
the	O
high	O
binding	O
affinities	O
have	O
common	O
chemical	O
structures	O
,	O
such	O
as	O
an	O
azole	O
ring	O
[	O
25	O
],	O
and	O
quarternary	O
nitrogen	O
[	O
26	O
].	O

3	O
.	O

In	O
HEK	O
482T	O
,	O
substrate	O
compounds	O
,	O
such	O
as	O
Caffeine	O
,	O
Diltiazem	O
,	O
Epinephrine	O
,	O
Estradiol	O
,	O
Raloxifene	O
and	O
Verapamil	O
,	O
did	O
not	O
significantly	O
affect	O
the	O
uptake	O
rate	O
of	O
Mitoxantrone	O
,	O
whereas	O
in	O
both	O
482R	O
and	O
482G	O
,	O
substrate	O
compounds	O
,	O
such	O
as	O
Foscarnet	O
and	O
Rhodamine	O
123	O
,	O
did	O
not	O
significantly	O
affect	O
the	O
uptake	O
rate	O
of	O
Mitoxantrone	O
.	O

Mitoxantrone	O
uptake	O
by	O
the	O
482	O
R	O
,	O
482	O
G	O
and	O
482	O
T	O
transfected	O
HEK	O
cells	O
in	O
the	O
presence	O
of	O
various	O
substrate	O
compounds	O
.	O
The	O
data	O
are	O
expressed	O
as	O
mean	O
+/−	O
SD	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
each	O
experiment	O
performed	O
in	O
quadruplicate	O
.	O

It	O
was	O
suggested	O
that	O
changes	O
in	O
the	O
uptake	O
amount	O
of	O
Mitoxantrone	O
in	O
the	O
presence	O
of	O
various	O
substrates	O
are	O
due	O
to	O
their	O
influence	O
toward	O
BCRP	B-GP
efflux	O
polymorphs	O
.	O

Although	O
an	O
indirect	O
approach	O
associated	O
with	O
the	O
uptake	O
rate	O
may	O
not	O
be	O
the	O
best	O
option	O
to	O
predict	O
the	O
relationship	O
with	O
the	O
chemical	O
structures	O
,	O
the	O
changes	O
in	O
the	O
uptake	O
rate	O
of	O
Mitoxantrone	O
in	O
the	O
presence	O
of	O
substrate	O
compounds	O
could	O
serve	O
as	O
a	O
valid	O
indicator	O
for	O
the	O
drug	O
affinity	O
to	O
BCRP	B-GP
.	O

Relationships	O
between	O
the	O
uptake	O
rates	O
and	O
chemical	O
properties	O

I	O
.	O

482R	O
Polymorphs	O

The	O
relationships	O
between	O
the	O
uptake	O
rates	O
and	O
the	O
chemical	O
structures	O
of	O
substrates	O
were	O
analyzed	O
and	O
quantitatively	O
expressed	O
as	O
the	O
concentration	O
of	O
a	O
substrate	O
required	O
to	O
exert	O
a	O
biological	O
response	O
.	O

As	O
shown	O
in	O
Table	O
1	O
,	O
four	O
descriptors	O
,	O
HOMO	O
-	O
1	O
energy	O
,	O
Max	O
atomic	O
orbital	O
electronic	O
population	O
,	O
ESP	O
-	O
Max	O
net	O
atomic	O
charge	O
and	O
average	O
electrophilic	O
reaction	O
index	O
for	O
a	O
O	O
atom	O
,	O
mainly	O
contribute	O
to	O
the	O
linear	O
relationship	O
profiles	O
in	O
a	O
QSAR	O
model	O
for	O
482R	O
polymorph	O
with	O
the	O
experimental	O
coefficient	O
value	O
R2	O
of	O
0	O
.	O
9740	O
(	O
F	O
=	O
56	O
.	O
17	O
s2	O
=	O
0	O
.	O
024	O
Q2	O
=	O
0	O
.	O
8561	O
:	O
Table	O
2	O
),	O
which	O
are	O
indicative	O
of	O
a	O
close	O
correlation	O
among	O
them	O
.	O

As	O
shown	O
in	O
Figure	O
2	O
,	O
the	O
prediction	O
power	O
of	O
the	O
test	O
substrates	O
was	O
also	O
within	O
5	O
%	O
of	O
the	O
experimental	O
value	O
,	O
which	O
further	O
corroborated	O
the	O
proposed	O
model	O
.	O

The	O
best	O
linear	O
models	O
computed	O
for	O
482	O
R	O
,	O
482	O
G	O
and	O
482	O
T	O
of	O
BCRP	B-GP

Type	O

The	O
Best	O
Linear	O
Model	O

482	O
R	O

R2	O
=	O
0	O
.	O
9740	O

F	O
=	O
56	O
.	O
17	O

s2	O
=	O
0	O
.	O
024	O

Q2	O
=	O
0	O
.	O
8561	O

(	O
4	O
,	O
RANK	O
)	O


X	O

DX	O

t	O
-	O
test	O

0	O

-	O
4	O
.	O
1145e	O
+	O
02	O

1	O
.	O
7878e	O
+	O
01	O

23	O
.	O
0141	O

Intercept	O

1	O

1	O
.	O
2538e	O
+	O
01	O

6	O
.	O
6354e	O
-	O
01	O

18	O
.	O
8958	O

HOMO	O
-	O
1	O
energy	O

2	O

2	O
.	O
9607e	O
+	O
02	O

9	O
.	O
1140e	O
+	O
00	O

32	O
.	O
4857	O

Max	O
atomic	O
orbital	O
electronic	O
population	O

3	O

-	O
1	O
.	O
0329e	O
+	O
01	O

5	O
.	O
3540e	O
-	O
01	O

19	O
.	O
2916	O

ESP	O
-	O
Max	O
net	O
atomic	O
charge	O

4	O

1	O
.	O
7837e	O
+	O
03	O

2	O
.	O
4776e	O
+	O
02	O

7	O
.	O
1996	O

Avg	O
electroph	O
.	O
react	O
.	O
index	O
for	O
a	O
O	O
atom	O

482	O
G	O

R2	O
=	O
0	O
.	O
8455	O

F	O
=	O
82	O
.	O
1	O

s2	O
=	O
0	O
.	O
0181	O

Q2	O
=	O
0	O
.	O
5986	O

(	O
4	O
,	O
RANK	O
)	O


X	O

DX	O

t	O
-	O
test	O

0	O

-	O
3	O
.	O
5513e	O
+	O
02	O

1	O
.	O
9119e	O
+	O
01	O

18	O
.	O
5750	O

Intercept	O

1	O

-	O
1	O
.	O
2124e	O
+	O
03	O

3	O
.	O
4838e	O
+	O
01	O

34	O
.	O
8023	O

ESP	O
-	O
Max	O
net	O
atomic	O
charge	O
2	O

2	O
.	O

0790e	O
+	O
02	O

6	O
.	O
3673e	O
+	O
00	O

32	O
.	O
6508	O

Max	O
SIGMA	O
-	O
PI	O
bond	O
order	O

3	O

3	O
.	O
5144e	O
+	O
01	O

1	O
.	O
6146e	O
+	O
00	O

21	O
.	O
7656	O

Max	O
1	O
-	O
electron	O
react	O
.	O
index	O
for	O
a	O
C	O
atom	O

4	O

2	O
.	O
4821e	O
+	O
01	O

4	O
.	O
9829e	O
+	O
00	O

4	O
.	O
9812	O

ESP	O
-	O
FPSA	O
-	O
1	O
Fractional	O
PPSA	O
(	O
PPSA	O
-	O
1	O
/	O
TMSA	O
)	O

[	O
Quantum	O
-	O
Chemical	O
PC	O
]	O

482	O
T	O

R2	O
=	O
0	O
.	O
8268	O

F	O
=	O
71	O
.	O
6	O

s2	O
=	O
0	O
.	O
027	O

Q2	O
=	O
0	O
.	O
5617	O

(	O
5	O
,	O
RANK	O
)	O



X	O

DX	O

t	O
-	O
test	O


0	O

2	O
.	O
0718e	O
+	O
02	O

4	O
.	O
8027e	O
+	O
01	O

4	O
.	O
3139	O

Intercept	O

1	O

5	O
.	O
4190e	O
+	O
01	O

7	O
.	O
7933e	O
+	O
00	O

6	O
.	O
9535	O

ESP	O
-	O
Max	O
net	O
atomic	O
charge	O

2	O

6	O
.	O
1209e	O
+	O
01	O

2	O
.	O
6032e	O
+	O
00	O

23	O
.	O
5132	O

ESP	O
-	O
Max	O
net	O
atomic	O
charge	O
for	O
a	O
N	O
atom	O

3	O

8	O
.	O
9479e	O
+	O
00	O

6	O
.	O
5221e	O
-	O
01	O

13	O
.	O
7193	O

Number	O
of	O
double	O
bonds	O

4	O

2	O
.	O
0862e	O
+	O
00	O

2	O
.	O
3046e	O
-	O
01	O

9	O
.	O
0521	O

min	O
(#	O
HA	O
,	O
#	O
HD	O
)	O
[	O
Quantum	O
-	O
Chemical	O
PC	O
]	O


5	O

7	O
.	O
9300e	O
-	O
01	O

1	O
.	O
9317e	O
-	O
01	O

4	O
.	O
1053	O

Min	O
e	O
-	O
n	O
attraction	O
for	O
a	O
C	O
-	O
C	O
bond	O

Computed	O
R2and	O
Q2values	O
of	O
the	O
linear	O
models	O
for	O
482	O
R	O
,	O
482	O
G	O
and	O
482	O
T	O
of	O
BCRP	B-GP


Sets	O

R2	O

Q2	O

482C	O

Training	O
set	O

0	O
.	O
9740	O

0	O
.	O
8561	O

Test	O
set	O

0	O
.	O
9960	O

0	O
.	O
8506	O

482G	O

Training	O
set	O

0	O
.	O
8455	O

0	O
.	O
5986	O

Test	O
set	O

0	O
.	O
9976	O

0	O
.	O
8336	O

482T	O

Training	O
set	O

0	O
.	O
8268	O

0	O
.	O
5617	O


Test	O
set	O

0	O
.	O
9755	O

0	O
.	O
8438	O

a	O
The	O
best	O
linear	O
model	O
for	O
482	O
R	O
BCRP	B-GP
(	O
R2	O
=	O
0	O
.	O
99	O
,	O
F	O
=	O
460	O
.	O
38	O
,	O
cross	O
validated	O
R2	O
=	O
0	O
.	O
95	O
).	O
b	O
:	O
The	O
validation	O
of	O
the	O
model	O
on	O
the	O
testing	O
data	O
set	O
.	O

It	O
was	O
noted	O
that	O
the	O
dynamics	O
of	O
the	O
aromatic	O
cores	O
and	O
the	O
alkyl	O
tails	O
can	O
affect	O
the	O
electronic	O
properties	O
.	O

The	O
highest	O
occupied	O
molecular	O
orbital	O
(	O
HOMO	O
)	O
and	O
the	O
lowest	O
unoccupied	O
molecular	O
orbital	O
(	O
LUMO	O
)	O
are	O
just	O
two	O
of	O
molecular	O
energy	O
levels	O
,	O
and	O
efficient	O
energy	O
conversion	O
is	O
an	O
integral	O
step	O
in	O
practical	O
applications	O
of	O
substrates	O
for	O
charge	O
transport	O
and	O
transfer	O
processes	O
through	O
efflux	B-GP
proteins	I-GP
or	O
transporters	B-GP
.	O

Another	O
important	O
descriptor	O
seems	O
to	O
be	O
overall	O
net	O
charge	O
and	O
surface	O
charge	O
of	O
substrates	O
.	O

As	O
the	O
atomic	O
charge	O
of	O
the	O
molecule	O
increases	O
,	O
the	O
modulation	O
of	O
the	O
uptake	O
rate	O
of	O
Mitoxantrone	O
decreases	O
(	O
X	O
-	O
axis	O
is	O
expressed	O
as	O
a	O
negative	O
absolute	O
value	O
),	O
indicating	O
that	O
the	O
charge	O
in	O
the	O
molecules	O
were	O
inversely	O
correlated	O
with	O
the	O
uptake	O
rates	O
by	O
BCRP	B-GP
482R	O
polymorphs	O
.	O

This	O
finding	O
is	O
in	O
a	O
good	O
agreement	O
with	O
the	O
previous	O
report	O
that	O
ABC	B-GP
transporters	I-GP
have	O
a	O
greater	O
affinity	O
to	O
positively	O
charged	O
molecules	O
which	O
serve	O
as	O
an	O
electron	O
accepting	O
functional	O
group	O
[	O
27	O
].	O

Phenethyl	O
Isothiocyanate	O
(	O
PEITC	O
),	O
which	O
showed	O
a	O
higher	O
affinity	O
to	O
482R	O
,	O
has	O
an	O
electropositive	O
property	O
originated	O
from	O
thiocyanate	O
functional	O
groups	O
which	O
may	O
contribute	O
to	O
its	O
strong	O
affinity	O
to	O
482R	O
.	O

On	O
the	O
other	O
hand	O
,	O
Substrates	O
,	O
such	O
as	O
caffeine	O
,	O
estradiol	O
and	O
verapamil	O
didn	O
’	O
t	O
significantly	O
affect	O
the	O
uptake	O
rate	O
of	O
Mitoxantrone	O
by	O
482R	O
polymorphs	O
.	O

II	O
.	O

482G	O
Polymorphs	O

The	O
results	O
of	O
the	O
study	O
with	O
482G	O
polymorph	O
were	O
most	O
properly	O
expressed	O
in	O
a	O
linear	O
QSAR	O
equation	O
consist	O
of	O
4	O
descriptors	O
,	O
which	O
are	O
ESP	O
-	O
Max	O
net	O
atomic	O
charge	O
,	O
Max	O
SIGMA	O
-	O
PI	O
bond	O
order	O
,	O
Max	O
1	O
-	O
electron	O
reaction	O
index	O
for	O
a	O
C	O
atom	O
,	O
and	O
ESP	O
-	O
FPSA	O
-	O
1	O
Fractional	O
PPSA	O
(	O
PPSA	O
-	O
1	O
/	O
TMSA	O
)	O
[	O
Quantum	O
-	O
Chemical	O
PC	O
],	O
with	O
the	O
correlation	O
coefficient	O
for	O
the	O
modulated	O
uptake	O
of	O
R2	O
of	O
0	O
.	O
8455	O
(	O
F	O
=	O
82	O
.	O
1	O
s2	O
=	O
0	O
.	O
0181	O
Q2	O
=	O
0	O
.	O
5986	O
),	O
as	O
shown	O
in	O
Tables	O
1	O
and	O
2	O
.	O

The	O
predicted	O
value	O
for	O
the	O
substrate	O
molecules	O
was	O
also	O
within	O
5	O
%	O
of	O
the	O
experimental	O
value	O
as	O
shown	O
in	O
Figure	O
3	O
.	O

Similar	O
to	O
the	O
results	O
of	O
482R	O
polymorph	O
,	O
it	O
was	O
also	O
demonstrated	O
that	O
affinity	O
of	O
the	O
482G	O
polymorph	O
to	O
BCRP	B-GP
decreases	O
,	O
as	O
the	O
charge	O
on	O
the	O
molecule	O
increases	O
.	O

The	O
correlation	O
coefficient	O
between	O
two	O
variables	O
(	O
i	O
.	O
e	O
.,	O
charge	O
and	O
binding	O
affinity	O
)	O
for	O
482G	O
polymorph	O
is	O
less	O
significant	O
than	O
that	O
of	O
482R	O
.	O

a	O
The	O
best	O
linear	O
model	O
for	O
482	O
T	O
BCRP	B-GP
(	O
R2	O
=	O
0	O
.	O
99	O
,	O
F	O
=	O
238	O
.	O
48	O
,	O
cross	O
validated	O
R2	O
=	O
0	O
.	O
99	O
).	O
b	O
:	O
The	O
validation	O
of	O
the	O
model	O
on	O
the	O
testing	O
data	O
set	O
.	O

Among	O
substrates	O
,	O
Phenethyl	O
Isothiocyanate	O
(	O
PEITC	O
)	O
has	O
the	O
highest	O
binding	O
affinity	O
to	O
482G	O
.	O

The	O
binding	O
affinity	O
of	O
Rhodamine123	O
to	O
482G	O
polymorph	O
is	O
lower	O
than	O
that	O
to	O
482R	O
.	O

Febendazole	O
and	O
Riboflavin	O
showed	O
a	O
low	O
binding	O
affinity	O
to	O
482G	O
,	O
mainly	O
due	O
to	O
the	O
presence	O
of	O
multiple	O
double	O
bonds	O
and	O
aromatic	O
rings	O
.	O

Substrates	O
,	O
such	O
as	O
Rhodamine123	O
(	O
123	O
%),	O
Estradiol	O
(	O
114	O
%)	O
and	O
Foscarnet	O
(	O
111	O
%),	O
did	O
not	O
significantly	O
affect	O
the	O
Mitoxantrone	O
uptake	O
rate	O
by	O
482R	O
polymorph	O
.	O

III	O
.	O

482T	O
Polymorph	O

As	O
shown	O
in	O
Table	O
1	O
,	O
a	O
linear	O
QSAR	O
for	O
482T	O
polymorph	O
consists	O
of	O
5	O
descriptors	O
;	O
ESP	O
-	O
Max	O
net	O
atomic	O
charge	O
,	O
ESP	O
-	O
Max	O
net	O
atomic	O
charge	O
for	O
a	O
N	O
atom	O
,	O
Number	O
of	O
double	O
bonds	O
,	O
min	O
(#	O
HA	O
,	O
#	O
HD	O
)	O
[	O
Quantum	O
-	O
Chemical	O
PC	O
],	O
and	O
Min	O
e	O
-	O
n	O
attraction	O
for	O
a	O
C	O
-	O
C	O
bond	O
.	O

The	O
correlation	O
value	O
for	O
the	O
modulated	O
uptake	O
rate	O
was	O
0	O
.	O
8268	O
(	O
F	O
=	O
71	O
.	O
6	O
,	O
s2	O
=	O
0	O
.	O
027	O
,	O
Q2	O
=	O
0	O
.	O
5617	O
)	O
and	O
the	O
predicted	O
power	O
of	O
the	O
test	O
molecules	O
was	O
within	O
5	O
%	O
of	O
the	O
experimental	O
outcomes	O
,	O
indicating	O
that	O
there	O
is	O
a	O
good	O
correlation	O
among	O
selected	O
parameters	O
.	O

As	O
shown	O
in	O
Figure	O
3	O
,	O
differing	O
from	O
the	O
results	O
of	O
482R	O
and	O
482G	O
polymorph	O
,	O
there	O
is	O
a	O
positive	O
relationship	O
between	O
surface	O
charge	O
and	O
binding	O
affinity	O
;	O
as	O
a	O
charge	O
on	O
the	O
molecule	O
increases	O
,	O
its	O
binding	O
affinity	O
to	O
482	O
T	O
polymorph	O
increases	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
presence	O
of	O
the	O
charged	O
residue	O
significantly	O
affects	O
the	O
affinity	O
of	O
test	O
substrates	O
even	O
though	O
it	O
does	O
not	O
substantially	O
contribute	O
to	O
the	O
specificity	O
to	O
each	O
BCRP	B-GP
polymorph	O
.	O

The	O
steric	O
factors	O
are	O
likely	O
to	O
play	O
a	O
vital	O
role	O
in	O
the	O
relationship	O
between	O
substrate	O
property	O
and	O
binding	O
affinity	O
,	O
even	O
though	O
their	O
contribution	O
to	O
the	O
binding	O
affinity	O
of	O
substrates	O
to	O
BCRP	B-GP
is	O
much	O
less	O
than	O
the	O
charged	O
residue	O
.	O

482T	O
polymorph	O
has	O
a	O
lower	O
affinity	O
towards	O
substrates	O
,	O
such	O
as	O
Caffeine	O
,	O
Diltiazem	O
,	O
Raloxifene	O
,	O
Quinidine	O
and	O
Verapamil	O
.	O

Fumitremorgin	O
C	O
(	O
FTC	O
)	O
showed	O
the	O
highest	O
impact	O
on	O
the	O
uptake	O
rate	O
of	O
Mitoxantrone	O
by	O
482T	O
,	O
which	O
is	O
probably	O
due	O
to	O
the	O
presence	O
of	O
the	O
charge	O
species	O
on	O
FTC	O
.	O

Since	O
the	O
side	O
effects	O
of	O
FTC	O
(	O
i	O
.	O
e	O
.,	O
neurotoxicity	O
)	O
arises	O
from	O
stereo	O
chemical	O
constraints	O
on	O
the	O
conformation	O
of	O
the	O
diketopiperazine	O
D	O
ring	O
,	O
the	O
replacement	O
of	O
the	O
proline	O
moiety	O
(	O
E	O
ring	O
)	O
by	O
an	O
acyclic	O
substituent	O
might	O
allow	O
the	O
adjacent	O
diketopiperazine	O
ring	O
to	O
assume	O
a	O
new	O
conformation	O
with	O
the	O
less	O
charge	O
species	O
that	O
renders	O
the	O
diastereoisomeric	O
mixtures	O
of	O
FTC	O
analogues	O
less	O
neurotoxic	O
than	O
native	O
FTC	O
[	O
28	O
,	O
29	O
].	O

Quercitin	O
,	O
which	O
is	O
known	O
as	O
the	O
most	O
active	O
reactive	O
oxygen	O
species	O
(	O
i	O
.	O
e	O
.,	O
peroxynitrite	O
)	O
scavenger	O
among	O
the	O
structural	O
analogues	O
of	O
flavonoids	O
,	O
had	O
a	O
significant	O
impact	O
on	O
the	O
uptake	O
rate	O
of	O
Mitoxantrone	O
in	O
all	O
three	O
polymorphs	O
,	O
probably	O
due	O
to	O
the	O
fact	O
that	O
Quercitin	O
has	O
high	O
resonance	O
and	O
donates	O
electrons	O
on	O
the	O
oxygen	O
atom	O
even	O
though	O
it	O
lacks	O
nitrogen	O
atoms	O
on	O
the	O
aromatic	O
ring	O
.	O

It	O
was	O
reported	O
that	O
molecule	O
oxygen	O
atom	O
on	O
C	O
-	O
4	O
of	O
C	O
ring	O
of	O
Quercetin	O
carries	O
the	O
largest	O
excess	O
charge	O
,	O
whereas	O
charge	O
accumulation	O
on	O
the	O
hydroxy	O
groups	O
at	O
the	O
same	O
ring	O
is	O
not	O
considerably	O
large	O
[	O
30	O
,	O
31	O
].	O

On	O
the	O
other	O
hand	O
,	O
estradiol	O
did	O
not	O
affect	O
the	O
uptake	O
rate	O
of	O
Mitoxantrone	O
in	O
all	O
three	O
polymorphs	O
,	O
indicating	O
that	O
estradiol	O
is	O
not	O
a	O
major	O
substrate	O
for	O
BCRP	B-GP
.	O

The	O
results	O
of	O
this	O
study	O
underline	O
importance	O
of	O
complement	B-GP
regulatory	I-GP
proteins	I-GP
in	O
the	O
biologic	O
systems	O
that	O
outline	O
the	O
binding	O
capacity	O
of	O
exogenous	O
compounds	O
and	O
subsequent	O
their	O
uptake	O
rates	O
.	O

IV	O
.	O

The	O
model	O
validation	O
process	O

The	O
Cross	O
Validation	O
process	O
was	O
carried	O
out	O
to	O
confirm	O
the	O
predicting	O
power	O
of	O
the	O
QSAR	O
model	O
.	O

The	O
error	O
values	O
of	O
the	O
coefficient	O
computed	O
through	O
QSAR	O
model	O
were	O
obtained	O
through	O
assessment	O
of	O
percentage	O
Absolute	O
Relative	O
Error	O
(	O
ARE	O
)	O
using	O
the	O
absolute	O
value	O
calculation	O
of	O
[(	O
Actual	O
Output	O
-	O
Predicted	O
Output	O
)/	O
Actual	O
Output	O
].	O

The	O
experimental	O
and	O
expected	O
values	O
of	O
each	O
compound	O
were	O
plotted	O
for	O
the	O
validation	O
process	O
as	O
shown	O
in	O
Figures	O
2b	O
,	O
4b	O
and	O
3b	O
for	O
482R	O
,	O
482G	O
and	O
482T	O
,	O
respectively	O
.	O

The	O
error	O
values	O
for	O
both	O
individual	O
and	O
combined	O
descriptors	O
were	O
within	O
10	O
%	O
of	O
the	O
predicted	O
values	O
(	O
Table	O
3	O
),	O
indicating	O
that	O
the	O
predicted	O
values	O
from	O
the	O
linear	O
model	O
are	O
in	O
good	O
agreement	O
with	O
the	O
experimental	O
values	O
.	O

It	O
was	O
also	O
proved	O
that	O
the	O
QSAR	O
can	O
accurately	O
predict	O
the	O
effects	O
of	O
various	O
substrates	O
on	O
the	O
uptake	O
rate	O
of	O
Mitoxantrone	O
based	O
on	O
the	O
given	O
set	O
of	O
variables	O
.	O

The	O
linear	O
relationships	O
with	O
the	O
experimental	O
coefficient	O
value	O
(	O
R2	O
)	O
and	O
cross	O
validate	O
coefficient	O
value	O
(	O
Q2	O
)	O
of	O
0	O
.	O
9	O
and	O
0	O
.	O
85	O
(	O
Figure	O
2b	O
),	O
0	O
.	O
99	O
and	O
0	O
.	O
83	O
(	O
Figure	O
3b	O
)	O
and	O
0	O
.	O
97	O
and	O
0	O
.	O
84	O
(	O
Figure	O
3b	O
)	O
for	O
482R	O
,	O
482G	O
and	O
482T	O
,	O
respectively	O
,	O
are	O
indicative	O
of	O
a	O
close	O
correlation	O
between	O
experimental	O
values	O
and	O
calculated	O
values	O
.	O

a	O
The	O
best	O
linear	O
model	O
for	O
482	O
G	O
BCRP	B-GP
(	O
R2	O
=	O
0	O
.	O
99	O
,	O
F	O
=	O
576	O
.	O
86	O
,	O
cross	O
validated	O
R2	O
=	O
0	O
.	O
90	O
).	O
b	O
:	O
The	O
validation	O
of	O
the	O
model	O
on	O
the	O
testing	O
data	O
set	O
.	O

Validation	O
of	O
the	O
uptake	O
rates	O
of	O
Mitoxantrone	O
for	O
the	O
testing	O
set	O
of	O
substrate	O
compounds	O
:	O
Correlation	O
between	O
the	O
experimental	O
values	O
of	O
testing	O
substrates	O
and	O
their	O
calculated	O
values	O
based	O
on	O
the	O
best	O
linear	O
model	O
for	O
each	O
polymorph	O
of	O
BCRP	B-GP

TEST	O
SET	O

482R	O

482R	O

482G	O

482G	O

482T	O

482T	O


Exp	O
.	O

Uptake	O
value	O

Cal	O
.	O

Uptake	O
value	O

Exp	O
.	O

Uptake	O
value	O

Cal	O
.	O

Uptake	O
value	O

Exp	O
.	O

Uptake	O
value	O

Cal	O
.	O

Uptake	O
value	O

Acyclovir	O

212	O

160	O

248	O

230	O

274	O

312	O

Epinephrine	O

181	O

188	O

123	O

119	O

115	O

105	O

Foscarnet	O

126	O

111	O

111	O

135	O

128	O

115	O

FumitremorginC	O

305	O

361	O

291	O

406	O

327	O

391	O

Ketoconazole	O

270	O

272	O

258	O

266	O

263	O

204	O

PEITC	O

288	O

266	O

313	O

346	O

329	O

355	O

Quercetin	O

247	O

274	O

252	O

269	O

239	O

288	O

The	O
results	O
of	O
this	O
study	O
suggested	O
that	O
the	O
binding	O
affinity	O
of	O
substrates	O
to	O
specific	O
receptors	O
or	O
efflux	B-GP
proteins	I-GP
is	O
not	O
entirely	O
dependent	O
on	O
a	O
particular	O
variable	O
or	O
an	O
individual	O
group	O
of	O
variables	O
in	O
the	O
relationship	O
,	O
but	O
it	O
is	O
rather	O
affected	O
by	O
various	O
combinations	O
of	O
variables	O
.	O

This	O
finding	O
further	O
supported	O
the	O
robustness	O
of	O
the	O
QSAR	O
approach	O
in	O
predicting	O
the	O
outcome	O
from	O
the	O
medical	O
database	O
by	O
avoiding	O
a	O
spurious	O
association	O
within	O
a	O
set	O
of	O
variables	O
.	O

It	O
was	O
also	O
suggested	O
that	O
descriptors	O
involved	O
with	O
the	O
drug	O
uptake	O
profiles	O
will	O
give	O
new	O
insights	O
on	O
chemical	O
modifications	O
that	O
can	O
lead	O
to	O
designing	O
new	O
chemotherapeutic	O
agent	O
with	O
improved	O
pharmacological	O
properties	O
.	O

To	O
design	O
a	O
pharmacologically	O
active	O
drug	O
for	O
site	O
-	O
specific	O
activity	O
is	O
a	O
challenging	O
task	O
that	O
begins	O
with	O
rationally	O
identifying	O
the	O
targets	O
to	O
which	O
that	O
drug	O
binds	O
.	O

There	O
are	O
a	O
number	O
of	O
computational	O
approaches	O
in	O
designing	O
efficient	O
therapeutics	O
based	O
on	O
target	O
identification	O
and	O
lead	O
optimization	O
.	O

As	O
the	O
specific	O
binding	O
to	O
active	O
targets	O
may	O
have	O
a	O
profound	O
impact	O
on	O
the	O
overall	O
pharmacological	O
activity	O
[	O
32	O
],	O
the	O
effects	O
of	O
a	O
variety	O
pattern	O
of	O
protein	O
binding	O
reflected	O
in	O
the	O
uptake	O
profiles	O
by	O
cell	O
membrane	O
on	O
therapeutic	O
efficacy	O
of	O
drugs	O
could	O
be	O
adapted	O
as	O
a	O
primary	O
screening	O
means	O
.	O

The	O
importance	O
of	O
protein	O
binding	O
has	O
already	O
been	O
validated	O
by	O
less	O
specific	O
protein	B-GP
kinase	I-GP
inhibitors	O
which	O
attack	O
tumors	B-DS
through	O
multiple	O
mechanisms	O
[	O
33	O
].	O

This	O
strategy	O
has	O
been	O
effective	O
to	O
more	O
than	O
one	O
type	O
of	O
cancer	B-DS
therapies	O
.	O

A	O
thorough	O
understanding	O
of	O
drug	O
binding	O
interactions	O
and	O
their	O
relationship	O
with	O
the	O
biological	O
activity	O
requires	O
high	O
-	O
throughput	O
computational	O
biology	O
approaches	O
.	O

Computational	O
techniques	O
that	O
identify	O
competitive	O
binding	O
substrates	O
and	O
their	O
inhibition	O
range	O
in	O
cellular	O
networks	O
have	O
been	O
intensively	O
developed	O
,	O
but	O
their	O
scales	O
are	O
very	O
limited	O
to	O
initial	O
assessment	O
process	O
[	O
6	O
,	O
34	O
].	O

Moreover	O
,	O
the	O
qualitative	O
description	O
of	O
the	O
chemical	O
entity	O
currently	O
available	O
showed	O
a	O
limited	O
predictive	O
power	O
due	O
to	O
the	O
high	O
dynamic	O
nature	O
of	O
molecular	O
structures	O
and	O
complicated	O
responses	O
from	O
biological	O
systems	O
including	O
complex	O
efflux	O
pathways	O
.	O

The	O
mathematical	O
modeling	O
approaches	O
,	O
such	O
as	O
ordinary	O
differential	O
equations	O
and	O
pi	O
-	O
calculus	O
,	O
have	O
limitations	O
in	O
that	O
they	O
require	O
a	O
large	O
number	O
of	O
kinetics	O
parameters	O
to	O
simulate	O
the	O
dynamic	O
behavior	O
of	O
the	O
biological	O
system	O
to	O
which	O
chemical	O
entities	O
bind	O
[	O
35	O
,	O
36	O
].	O

Therefore	O
,	O
a	O
functional	O
dynamic	O
model	O
based	O
on	O
the	O
qualitative	O
descriptors	O
defined	O
from	O
the	O
competitive	O
uptake	O
profiles	O
is	O
integral	O
for	O
parameter	O
optimization	O
and	O
dose	O
regimen	O
specification	O
of	O
new	O
drug	O
entities	O
.	O

In	O
recent	O
years	O
,	O
major	O
efforts	O
have	O
been	O
placed	O
on	O
identifying	O
and	O
characterizing	O
ABC	B-GP
transporters	I-GP
.	O

They	O
are	O
expressed	O
at	O
the	O
major	O
barriers	O
within	O
the	O
body	O
(	O
e	O
.	O
g	O
.,	O
intestine	O
,	O
blood	O
–	O
brain	O
barrier	O
,	O
placenta	O
,	O
kidney	O
,	O
and	O
liver	O
),	O
where	O
they	O
lowered	O
the	O
uptake	O
rate	O
or	O
enhanced	O
the	O
clearance	O
of	O
drugs	O
[	O
37	O
].	O

Breast	B-GP
Cancer	I-GP
Resistant	I-GP
Protein	I-GP
(	O
BCRP	B-GP
)	O
is	O
one	O
of	O
the	O
most	O
recently	O
discovered	O
members	O
of	O
ABC	B-GP
transporters	I-GP
.	O

BCRP	B-GP
is	O
a	O
homo	O
-	O
dimer	O
and	O
consists	O
of	O
655	O
amino	O
acids	O
containing	O
a	O
nuclear	O
binding	O
domain	O
and	O
a	O
membrane	O
spanning	O
domain	O
.	O

BCRP	B-GP
shares	O
broad	O
similarities	O
with	O
bacterial	O
,	O
yeast	B-OG
,	O
insect	B-OG
and	O
other	O
mammalian	O
ABC	B-GP
transporter	I-GP
proteins	O
[	O
38	O
].	O

In	O
normal	O
human	B-OG
tissues	O
,	O
BCRP	B-GP
was	O
detected	O
at	O
higher	O
levels	O
in	O
the	O
placenta	O
and	O
at	O
lower	O
levels	O
in	O
the	O
brain	O
,	O
prostate	O
,	O
ovary	O
,	O
colon	O
,	O
testis	O
,	O
liver	O
,	O
small	O
intestine	O
,	O
kidney	O
and	O
heart	O
[	O
22	O
,	O
39	O
].	O

Among	O
normal	O
tissues	O
,	O
BCRP	B-GP
is	O
expressed	O
in	O
sycytiotrophoblasts	O
of	O
placenta	O
,	O
epithelium	O
of	O
small	O
intestine	O
,	O
colon	O
,	O
liver	O
,	O
ducts	O
and	O
lobules	O
of	O
breast	O
,	O
and	O
haemopoietic	O
stem	O
cells	O
[	O
22	O
,	O
40	O
].	O

ABC	B-GP
transporters	I-GP
comprise	O
various	O
efflux	B-GP
proteins	I-GP
,	O
some	O
of	O
which	O
exert	O
abnormal	O
responses	O
to	O
exogenous	O
compounds	O
due	O
to	O
the	O
presence	O
of	O
polymorphs	O
.	O

Nine	O
polymorphs	O
have	O
been	O
identified	O
for	O
MDR	B-GP
-	I-GP
1	I-GP
[	O
41	O
].	O

In	O
a	O
clinical	O
trial	O
,	O
ABCG2	B-GP
polymorphism	O
has	O
a	O
vital	O
role	O
in	O
delineating	O
the	O
effective	O
dose	O
in	O
chemotherapy	O
[	O
42	O
].	O

Genetic	O
polymorphism	O
in	O
ABC	B-GP
transporters	I-GP
influences	O
numerous	O
diseases	O
including	O
hypertension	B-DS
[	O
43	O
],	O
lung	O
cancer	B-DS
[	O
44	O
]	O
and	O
colon	O
cancer	B-DS
[	O
45	O
].	O

The	O
mutation	O
of	O
polymorphs	O
discovered	O
from	O
human	B-OG
BCRP	B-GP
serves	O
an	O
integral	O
criterion	O
for	O
the	O
differential	O
affinity	O
of	O
substrates	O
to	O
BCRP	B-GP
[	O
46	O
].	O

It	O
was	O
found	O
that	O
the	O
affinity	O
of	O
BCRP	B-GP
to	O
substrates	O
can	O
be	O
modulated	O
by	O
altering	O
the	O
substrate	O
specificity	O
of	O
multi	B-GP
-	I-GP
drug	I-GP
transporters	I-GP
.	O

Several	O
BCRP	B-GP
variants	O
from	O
direct	O
DNA	O
sequencing	O
of	O
the	O
BCRP	B-GP
gene	O
have	O
been	O
reported	O
[	O
47	O
].	O

It	O
was	O
also	O
demonstrated	O
that	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
of	O
BCRP	B-GP
produced	O
individual	O
variations	O
in	O
the	O
pharmacokinetics	O
and	O
toxicity	O
profiles	O
of	O
BCRP	B-GP
substrates	O
.	O

BCRP	B-GP
G34A	O
(	O
Val12Met	O
)	O
and	O
C421A	O
(	O
Gln141Lys	O
)	O
polymorphisms	O
occurred	O
at	O
high	O
frequency	O
in	O
most	O
ethnic	O
populations	O
and	O
have	O
been	O
associated	O
with	O
the	O
expression	O
and	O
activity	O
of	O
BCRP	B-GP
protein	O
[	O
48	O
].	O

It	O
has	O
distinctive	O
features	O
including	O
racial	O
differences	O
;	O
for	O
instance	O
,	O
BCRP	B-GP
V12M	O
,	O
Q141K	O
,	O
P269S	O
and	O
Q126Stop	O
were	O
detected	O
in	O
Korean	O
at	O
frequencies	O
of	O
23	O
,	O
28	O
,	O
0	O
.	O
2	O
and	O
1	O
.	O
9	O
%,	O
respectively	O
[	O
49	O
].	O

This	O
study	O
was	O
undertaken	O
to	O
define	O
various	O
physicodynamic	O
and	O
chemical	O
properties	O
of	O
substrates	O
to	O
BCRP	B-GP
polymorphs	O
and	O
elucidate	O
the	O
rationales	O
behind	O
their	O
efficacies	O
.	O

The	O
structurally	O
diverse	O
compounds	O
were	O
evaluated	O
for	O
elucidation	O
of	O
the	O
BCRP	B-GP
polymorph	O
mediated	O
uptakes	O
and	O
establishment	O
of	O
the	O
relationships	O
with	O
their	O
molecular	O
structures	O
.	O

The	O
results	O
of	O
this	O
study	O
suggested	O
that	O
the	O
chemical	O
properties	O
of	O
exogenous	O
compounds	O
significantly	O
influence	O
BCRP	B-GP
polymorphs	O
mediated	O
uptake	O
rate	O
.	O

All	O
the	O
compounds	O
tested	O
in	O
this	O
study	O
are	O
either	O
substrates	O
or	O
inhibitors	O
of	O
at	O
least	O
one	O
of	O
BCRP	B-GP
polymorphs	O
.	O

The	O
analysis	O
on	O
the	O
chemical	O
properties	O
of	O
the	O
substrates	O
based	O
on	O
the	O
combining	O
AMPAC	O
/	O
CPDESSA	O
approach	O
could	O
help	O
us	O
to	O
identify	O
integral	O
descriptors	O
that	O
should	O
be	O
mirrored	O
by	O
interactions	O
with	O
receptor	O
proteins	O
[	O
50	O
].	O

In	O
this	O
study	O
,	O
the	O
consistent	O
appearance	O
of	O
surface	O
charge	O
,	O
electrophilic	O
reactivity	O
indices	O
and	O
molecular	O
orbital	O
energy	O
descriptors	O
obtained	O
from	O
the	O
sets	O
of	O
chemotherapeutic	O
substrate	O
compounds	O
supported	O
the	O
proven	O
concept	O
that	O
charged	O
electrophiles	O
with	O
the	O
high	O
energy	O
level	O
affected	O
the	O
affinity	O
to	O
BCRP	B-GP
polymorphs	O
.	O

The	O
quantum	O
chemical	O
descriptors	O
of	O
the	O
substrates	O
,	O
such	O
as	O
atomic	O
orbital	O
electronic	O
population	O
and	O
bond	O
order	O
,	O
also	O
significantly	O
contribute	O
to	O
its	O
affinity	O
to	O
BCRP	B-GP
polymorph	O
.	O

It	O
is	O
known	O
that	O
the	O
docking	O
analysis	O
of	O
descriptors	O
provides	O
a	O
qualitative	O
representation	O
of	O
ligand	O
and	O
protein	O
interactions	O
in	O
the	O
QSAR	O
model	O
,	O
even	O
though	O
the	O
selection	O
of	O
docked	O
conformations	O
is	O
often	O
complicated	O
due	O
to	O
its	O
sensitivity	O
to	O
the	O
scoring	O
function	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
substrate	O
compounds	O
containing	O
net	O
charged	O
radicals	O
can	O
activate	O
efflux	B-GP
proteins	I-GP
or	O
peptides	O
in	O
the	O
complement	O
system	O
.	O

There	O
is	O
also	O
a	O
close	O
correlation	O
between	O
descriptors	O
and	O
molecular	O
weight	O
,	O
especially	O
for	O
bulky	O
groups	O
.	O

The	O
steric	O
contour	O
analysis	O
indicates	O
that	O
the	O
addition	O
of	O
bulky	O
groups	O
in	O
the	O
active	O
region	O
reduces	O
the	O
binding	O
affinity	O
.	O

It	O
is	O
possible	O
that	O
subjects	O
with	O
these	O
polymorphisms	O
may	O
have	O
different	O
levels	O
of	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
expression	O
level	O
and	O
cellular	O
localization	O
and	O
,	O
consequently	O
,	O
varying	O
degrees	O
of	O
efflux	O
capability	O
to	O
model	O
compounds	O
[	O
51	O
].	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
which	O
level	O
and	O
sites	O
of	O
SNP	O
mainly	O
contribute	O
to	O
the	O
specificity	O
of	O
BCRP	B-GP
bindings	O
.	O

The	O
findings	O
in	O
this	O
study	O
provide	O
rationales	O
behind	O
the	O
development	O
of	O
new	O
drugs	O
whose	O
working	O
mechanisms	O
are	O
closely	O
correlated	O
with	O
substrate	O
or	O
inhibitor	O
properties	O
against	O
BCRP	B-GP
polymorphs	O
.	O

The	O
results	O
of	O
this	O
study	O
can	O
lead	O
to	O
detailed	O
constitutional	O
descriptors	O
that	O
can	O
be	O
directly	O
translated	O
to	O
a	O
chemical	O
structure	O
,	O
such	O
as	O
connectivity	O
indices	O
and	O
descriptors	O
describing	O
substitution	O
patterns	O
.	O

It	O
is	O
possible	O
to	O
combine	O
and	O
translate	O
calculated	O
properties	O
of	O
descriptors	O
into	O
a	O
new	O
chemical	O
/	O
pharmaceutical	O
entity	O
through	O
the	O
visualization	O
process	O
by	O
the	O
contour	O
map	O
and	O
an	O
analyzing	O
tool	O
like	O
GaussView	O
program	O
(	O
GaussView	O
3	O
.	O
07	O
:	O
Gaussian	O
Inc	O
.,	O
Wallingford	O
,	O
CT	O
).	O

It	O
is	O
certain	O
that	O
numerous	O
training	O
compounds	O
need	O
to	O
span	O
through	O
the	O
model	O
fitting	O
techniques	O
,	O
addressing	O
not	O
only	O
finding	O
a	O
fit	O
,	O
but	O
also	O
the	O
predictive	O
feature	O
of	O
the	O
fit	O
.	O

While	O
the	O
outcomes	O
of	O
this	O
study	O
have	O
not	O
directly	O
steered	O
us	O
to	O
a	O
new	O
compound	O
,	O
they	O
have	O
helped	O
us	O
to	O
identify	O
important	O
structural	O
insight	O
into	O
optimal	O
designing	O
of	O
new	O
chemotherapeutic	O
agents	O
.	O

Recently	O
,	O
a	O
drug	O
class	O
called	O
poly	B-GP
ADP	I-GP
ribose	I-GP
polymerase	I-GP
(	O
PARP	B-GP
)	O
inhibitors	O
that	O
targets	O
cancers	B-DS
caused	O
by	O
BRCA	B-GP
mutations	O
have	O
shown	O
promise	O
in	O
clinical	O
trials	O
treating	O
breast	B-DS
cancer	I-DS
[	O
52	O
].	O

Conclusions	O

In	O
summary	O
,	O
the	O
chemotherapeutic	O
effects	O
of	O
the	O
known	O
substrates	O
were	O
classified	O
based	O
on	O
their	O
binding	O
affinity	O
to	O
BCRP	B-GP
.	O

The	O
computational	O
approach	O
with	O
the	O
sequential	O
approaches	O
of	O
Austin	O
Model	O
1	O
(	O
AM1	O
),	O
CODESSA	O
program	O
,	O
heuristic	O
method	O
(	O
HM	O
)	O
and	O
multiple	O
linear	O
regression	O
(	O
MLR	O
)	O
was	O
performed	O
to	O
derive	O
QSAR	O
model	O
and	O
its	O
predictive	O
power	O
was	O
validated	O
.	O

The	O
BCRP	B-GP
mutations	O
may	O
induce	O
conformational	O
changes	O
as	O
manifested	O
by	O
the	O
altered	O
uptake	O
rates	O
of	O
Mitoxantrone	O
by	O
BCRP	B-GP
in	O
the	O
presence	O
of	O
other	O
competitive	O
binding	O
substrates	O
that	O
have	O
a	O
varying	O
degree	O
of	O
affinities	O
toward	O
BCRP	B-GP
efflux	O
.	O

At	O
the	O
practical	O
level	O
,	O
the	O
use	O
of	O
a	O
computational	O
structural	O
approach	O
will	O
help	O
the	O
scientists	O
identify	O
the	O
best	O
compound	O
and	O
its	O
linear	O
dose	O
range	O
with	O
improved	O
pharmacological	O
efficacy	O
,	O
eliminating	O
the	O
need	O
to	O
perform	O
multiple	O
assays	O
over	O
a	O
wide	O
range	O
of	O
concentrations	O
in	O
defining	O
the	O
binding	O
affinity	O
and	O
uptake	O
rates	O
.	O

Methods	O

HEK	O
(	O
human	B-OG
embryonic	O
kidney	O
)	O
cell	O
lines	O
transfected	O
with	O
each	O
polymorph	O
(	O
i	O
.	O
e	O
.,	O
482R	O
,	O
482G	O
and	O
482T	O
)	O
were	O
kindly	O
donated	O
by	O
NIC	O
(	O
NIH	O
,	O
Bethesda	O
,	O
MD	O
)	O
[	O
53	O
].	O

The	O
minimum	O
essential	O
medium	O
was	O
purchased	O
from	O
ATCC	O
(	O
Manassas	O
,	O
VA	O
).	O

Penicillin	O
,	O
Streptomycin	O
,	O
and	O
Geneticin	O
were	O
purchased	O
from	O
Invitrogen	O
(	O
Carlsbad	O
,	O
CA	O
).	O

Radioactive	O
Mitoxantrone	O
was	O
obtained	O
from	O
American	O
Radiolabelled	O
Inc	O
(	O
St	O
Louis	O
,	O
MO	O
).	O

All	O
other	O
chemicals	O
and	O
testing	O
compounds	O
were	O
obtained	O
from	O
Sigma	O
(	O
St	O
Louis	O
,	O
MO	O
).	O

Cell	O
culture	O
preparation	O

HEK	O
cell	O
lines	O
transfected	O
with	O
482R	O
,	O
482G	O
and	O
482T	O
plasmids	O
were	O
grown	O
in	O
the	O
minimum	O
essential	O
medium	O
supplemented	O
with	O
10	O
%	O
FBS	O
,	O
50	O
IU	O
/	O
ml	O
penicillin	O
,	O
50	O
μg	O
/	O
ml	O
streptomycin	O
,	O
4	O
mM	O
L	O
-	O
glutamine	O
and	O
100	O
nM	O
Geneticin	O
.	O

Cells	O
were	O
incubated	O
in	O
75	O
mm2	O
plastic	O
culture	O
flasks	O
at	O
37	O
°	O
C	O
supplemented	O
with	O
5	O
%	O
CO2	O
/	O
95	O
%	O
air	O
.	O

BCRP	B-GP
expression	O
in	O
HEK	O
cells	O
was	O
confirmed	O
by	O
RT	O
-	O
PCR	O
using	O
the	O
method	O
previously	O
described	O
[	O
54	O
].	O

A	O
drug	O
uptake	O
study	O

HEK	O
cells	O
were	O
trypsinized	O
and	O
loaded	O
in	O
24	O
well	O
plates	O
at	O
a	O
seeding	O
density	O
of	O
2	O
×	O
105	O
cells	O
per	O
well	O
.	O

Cell	O
viability	O
was	O
maintained	O
by	O
providing	O
a	O
fresh	O
medium	O
every	O
other	O
day	O
until	O
they	O
reached	O
confluence	O
.	O

Cells	O
were	O
exposed	O
with	O
radioactive	O
Mitoxantrone	O
(~	O
100	O
μM	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
various	O
inhibitors	O
at	O
specific	O
concentrations	O
or	O
10	O
μM	O
Fumitremorgin	O
C	O
(	O
FTC	O
)	O
(	O
as	O
a	O
positive	O
control	O
)	O
at	O
37	O
°	O
C	O
for	O
5	O
min	O
.	O

The	O
drug	O
uptake	O
process	O
was	O
stopped	O
by	O
washing	O
the	O
cells	O
with	O
1	O
ml	O
of	O
ice	O
-	O
cold	O
DPBS	O
for	O
3	O
times	O
,	O
followed	O
by	O
lysis	O
with	O
the	O
Triton	O
X	O
/	O
0	O
.	O
1	O
M	O
NaOH	O
solution	O
.	O

A	O
cell	O
digest	O
(	O
100	O
μl	O
)	O
was	O
taken	O
and	O
diluted	O
to	O
5	O
ml	O
with	O
30	O
%	O
Scintisafe	O
™	O
(	O
Fisher	O
Scientific	O
,	O
NJ	O
).	O

The	O
cumulative	O
amount	O
of	O
Mitoxantrone	O
in	O
diluted	O
samples	O
was	O
determined	O
using	O
Beckman	O
Coulter	O
Counter	O
and	O
expressed	O
as	O
the	O
percentage	O
amount	O
of	O
the	O
control	O
.	O

Mitoxantrone	O
accumulation	O
was	O
normalized	O
for	O
cellular	O
protein	O
and	O
presented	O
as	O
the	O
percentage	O
of	O
the	O
control	O
,	O
where	O
the	O
control	O
represents	O
cells	O
treated	O
with	O
Mitoxantrone	O
in	O
the	O
absence	O
of	O
any	O
inhibitors	O
.	O

Data	O
were	O
expressed	O
as	O
mean	O
+/−	O
SD	O
,	O
p	O
<	O
0	O
.	O
05	O
and	O
by	O
one	O
way	O
ANOVA	O
.	O

A	O
drug	O
permeability	O
study	O

HEK	O
cell	O
lines	O
were	O
prepared	O
as	O
described	O
previously	O
[	O
54	O
].	O

After	O
confluence	O
was	O
achieved	O
,	O
the	O
TEER	O
value	O
of	O
cells	O
was	O
measured	O
to	O
verify	O
the	O
presence	O
of	O
tight	O
junction	O
.	O

The	O
growth	O
medium	O
was	O
replaced	O
and	O
washed	O
with	O
PBS	O
.	O

The	O
radioactive	O
Mitoxantrone	O
(~	O
100	O
μM	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
inhibitors	O
was	O
added	O
on	O
the	O
basolateral	O
side	O
of	O
the	O
transwells	O
.	O

The	O
samples	O
were	O
collected	O
from	O
the	O
apical	O
side	O
at	O
predetermined	O
time	O
intervals	O
for	O
up	O
to	O
120	O
min	O
.	O

Apparent	O
drug	O
permeability	O
(	O
Papp	O
)	O
value	O
was	O
calculated	O
using	O
the	O
formula	O
Papp	O
=	O
(	O
dQ	O
/	O
dt	O
)/(	O
A	O
x	O
D0	O
),	O
where	O
(	O
dQ	O
/	O
dt	O
)	O
is	O
the	O
linear	O
appearance	O
rate	O
of	O
drug	O
in	O
the	O
apical	O
side	O
,	O
A	O
is	O
the	O
cross	O
-	O
sectional	O
area	O
of	O
the	O
Transwell	O
insert	O
and	O
D0	O
is	O
the	O
initial	O
concentration	O
of	O
the	O
compound	O
in	O
the	O
baso	O
-	O
lateral	O
compartment	O
[	O
55	O
].	O

The	O
experiment	O
was	O
repeated	O
for	O
4	O
times	O
for	O
each	O
inhibitor	O
(	O
N	O
=	O
4	O
).	O

The	O
selection	O
of	O
datasets	O

As	O
shown	O
in	O
Table	O
4	O
,	O
the	O
substrates	O
selected	O
according	O
to	O
the	O
different	O
pharmacological	O
categories	O
were	O
evaluated	O
for	O
their	O
effects	O
on	O
the	O
flux	O
rates	O
of	O
Mitoxantrone	O
.	O

The	O
experimental	O
sets	O
(	O
25	O
)	O
were	O
divided	O
into	O
18	O
training	O
sets	O
and	O
7	O
test	O
sets	O
(	O
i	O
.	O
e	O
.,	O
for	O
validation	O
purpose	O
).	O

The	O
structures	O
of	O
the	O
substrates	O
in	O
the	O
training	O
set	O
are	O
shown	O
in	O
Figure	O
5	O
.	O

The	O
uptake	O
rates	O
for	O
Mitoxantrone	O
or	O
those	O
in	O
the	O
presence	O
of	O
the	O
substrates	O
obtained	O
from	O
the	O
experimental	O
transport	O
study	O
were	O
considered	O
to	O
be	O
directly	O
proportional	O
to	O
the	O
affinity	O
and	O
/	O
or	O
permeation	O
rate	O
of	O
drugs	O
with	O
BCRP	B-GP
.	O

The	O
changes	O
in	O
the	O
uptake	O
rate	O
of	O
Mitoxantrone	O
in	O
482	O
R	O
,	O
482	O
G	O
and	O
482	O
T	O
BCRP	B-GP
transfected	O
HEK	O
cell	O
line	O
in	O
the	O
presence	O
of	O
substrate	O
compounds	O



Changes	O
in	O
Uptake	O
of	O
Mitoxantrone	O
(	O
cm	O
/	O
sec	O
:	O
%)	O



482R	O

482G	O

482T	O


Mitoxantrone	O

23	O
.	O
71	O
(	O
100	O
%)	O

27	O
.	O
43	O
(	O
100	O
%)	O

25	O
.	O
92	O
(	O
100	O
%)	O

Training	O
Set	O

Caffeine	O

29	O
.	O
64	O
(	O
125	O
%)	O

41	O
.	O
42	O
(	O
151	O
%)	O

46	O
.	O
28	O
(	O
140	O
%)	O

Ciprofloxacin	O

57	O
.	O
38	O
(	O
242	O
%)	O

63	O
.	O
91	O
(	O
233	O
%)	O

45	O
.	O
88	O
(	O
177	O
%)	O

Cyclosporin	O

70	O
.	O
18	O
(	O
296	O
%)	O

66	O
.	O
93	O
(	O
244	O
%)	O

63	O
.	O
76	O
(	O
246	O
%)	O

Diltiazem	O

55	O
.	O
95	O
(	O
236	O
%)	O

59	O
.	O
52	O
(	O
217	O
%)	O

32	O
.	O
40	O
(	O
125	O
%)	O

Erythromycin	O

37	O
.	O
93	O
(	O
160	O
%)	O

48	O
.	O
00	O
(	O
175	O
%)	O

50	O
.	O
02	O
(	O
193	O
%)	O

Estradiol	O

29	O
.	O
87	O
(	O
126	O
%)	O

31	O
.	O
27	O
(	O
114	O
%)	O

26	O
.	O
70	O
(	O
103	O
%)	O

Febendazole	O

30	O
.	O
82	O
(	O
130	O
%)	O

34	O
.	O
83	O
(	O
127	O
%)	O

38	O
.	O
36	O
(	O
148	O
%)	O

Ketoconazole	O

64	O
.	O
50	O
(	O
272	O
%)	O

70	O
.	O
22	O
(	O
256	O
%)	O

68	O
.	O
17	O
(	O
263	O
%)	O

Nifedipine	O

38	O
.	O
17	O
(	O
161	O
%)	O

42	O
.	O
52	O
(	O
155	O
%)	O

38	O
.	O
36	O
(	O
148	O
%)	O

Novobiocin	O

56	O
.	O
90	O
(	O
240	O
%)	O

77	O
.	O
35	O
(	O
282	O
%)	O

71	O
.	O
02	O
(	O
274	O
%)	O

Quinidine	O

38	O
.	O
64	O
(	O
163	O
%)	O

41	O
.	O
97	O
(	O
153	O
%)	O

33	O
.	O
17	O
(	O
128	O
%)	O

Raloxifene	O

46	O
.	O
47	O
(	O
196	O
%)	O

55	O
.	O
95	O
(	O
204	O
%)	O

23	O
.	O
58	O
(	O
91	O
%)	O

Rhodamine	O
123	O

44	O
.	O
57	O
(	O
188	O
%)	O

33	O
.	O
74	O
(	O
123	O
%)	O

43	O
.	O
02	O
(	O
166	O
%)	O

Riboflavin	O

41	O
.	O
25	O
(	O
174	O
%)	O

35	O
.	O
92	O
(	O
131	O
%)	O

36	O
.	O
80	O
(	O
142	O
%)	O

Saquinavir	O

46	O
.	O
00	O
(	O
194	O
%)	O

57	O
.	O
33	O
(	O
209	O
%)	O

72	O
.	O
83	O
(	O
281	O
%)	O

Tamoxifene	O

31	O
.	O
30	O
(	O
132	O
%)	O

38	O
.	O
67	O
(	O
141	O
%)	O

40	O
.	O
95	O
(	O
158	O
%)	O

Verapamil	O

29	O
.	O
87	O
(	O
126	O
%)	O

58	O
.	O
42	O
(	O
213	O
%)	O

31	O
.	O
36	O
(	O
121	O
%)	O

Test	O
Set	O

Acyclovir	O

50	O
.	O
26	O
(	O
212	O
%)	O

66	O
.	O
91	O
(	O
244	O
%)	O

68	O
.	O
95	O
(	O
266	O
%)	O

Epinephrine	O

42	O
.	O
91	O
(	O
181	O
%)	O

33	O
.	O
73	O
(	O
123	O
%)	O

24	O
.	O
89	O
(	O
115	O
%)	O

Foscarnet	O

29	O
.	O
87	O
(	O
126	O
%)	O

30	O
.	O
45	O
(	O
111	O
%)	O

33	O
.	O
17	O
(	O
128	O
%)	O

FumitremorginC	O

26	O
.	O
76	O
(	O
305	O
%)	O

79	O
.	O
82	O
(	O
291	O
%)	O

84	O
.	O
75	O
(	O
327	O
%)	O

Ketoconazole	O

64	O
.	O
02	O
(	O
270	O
%)	O

70	O
.	O
77	O
(	O
258	O
%)	O

68	O
.	O
17	O
(	O
263	O
%)	O

PEITC	O

68	O
.	O
28	O
(	O
288	O
%)	O

85	O
.	O
85	O
(	O
313	O
%)	O

85	O
.	O
27	O
(	O
329	O
%)	O


Quercetin	O

58	O
.	O
56	O
(	O
247	O
%)	O

69	O
.	O
12	O
(	O
252	O
%)	O

61	O
.	O
95	O
(	O
239	O
%)	O

The	O
data	O
are	O
expressed	O
as	O
mean	O
+/−	O
SD	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
each	O
experiment	O
performed	O
in	O
quadruplicate	O
.	O

Structures	O
of	O
Mitoxantrone	O
and	O
substrates	O
tested	O
in	O
this	O
study	O
.	O

A	O
QSAR	O
approach	O

This	O
approach	O
was	O
intended	O
to	O
select	O
the	O
most	O
suitable	O
descriptors	O
among	O
the	O
descriptor	O
sets	O
for	O
defining	O
binding	O
specificity	O
of	O
each	O
polymorph	O
.	O

Three	O
dimensional	O
structures	O
of	O
the	O
substrates	O
were	O
built	O
using	O
AMPAC	O
with	O
Graphical	O
User	O
Interface	O
(	O
Semichem	O
,	O
Shawnee	O
Mission	O
,	O
KS	O
)	O
[	O
56	O
].	O

For	O
structural	O
classification	O
of	O
descriptors	O
,	O
AMPAC	O
used	O
Austin	O
Model	O
1	O
(	O
AM1	O
),	O
which	O
is	O
the	O
Hamiltonian	O
widely	O
utilized	O
in	O
the	O
quantum	O
mechanical	O
semi	O
-	O
empirical	O
calculations	O
of	O
interactive	O
energy	O
.	O

AM1	O
achieved	O
energy	O
minimization	O
of	O
the	O
gradient	O
norm	O
(	O
0	O
.	O
05	O
kcal	O
/	O
mol	O
)	O
using	O
20	O
simplex	O
iterations	O
followed	O
by	O
1000	O
steps	O
of	O
Powell	O
minimization	O
[	O
57	O
].	O

CODESSA	O
(	O
Comprehensive	O
Descriptors	O
for	O
Structural	O
and	O
Statistical	O
Analysis	O
;	O
Semichem	O
,	O
Shawnee	O
Mission	O
,	O
KS	O
)	O
is	O
an	O
advanced	O
,	O
full	O
featured	O
Quantitative	O
Structure	O
/	O
Activity	O
Relationship	O
(	O
QSAR	O
)	O
program	O
that	O
connects	O
information	O
from	O
AMPAC	O
to	O
experimental	O
data	O
[	O
58	O
].	O

CODESSA	O
preselects	O
each	O
subset	O
of	O
structure	O
descriptors	O
,	O
which	O
include	O
constitutional	O
,	O
topographical	O
,	O
geometrical	O
,	O
electrostatic	O
,	O
thermodynamic	O
and	O
quantum	O
chemical	O
properties	O
,	O
as	O
shown	O
in	O
Table	O
5	O
.	O

CODESSA	O
can	O
generate	O
the	O
numerical	O
values	O
for	O
up	O
to	O
600	O
molecular	O
descriptors	O
which	O
can	O
be	O
used	O
for	O
the	O
regression	O
analysis	O
[	O
59	O
].	O

Descriptors	O
used	O
in	O
this	O
study	O
for	O
identifying	O
the	O
best	O
linear	O
model	O

Class	O

Name	O
of	O
Descriptors	O

Constitutional	O

Number	O
of	O
double	O
bonds	O

Number	O
of	O
aromatic	O
bonds	O

Number	O
of	O
Oxygen	O
atoms	O

Average	O
distance	O
sum	O
connectivity	O
index	O

ESP	O
-	O
RNCS	O
:	O
Relative	O
negative	O
charged	O
SA	O
(	O
SAMNEG	O
*	O
RNCG	O
)	O

ESP	O
-	O
RPCS	O
Relative	O
positive	O
charge	O
SA	O
(	O
QMPOS	O
/	O
QTPLUS	O
)	O

[	O
Zefirov	O
’	O
s	O
PC	O
]	O

WPSA3	O
weighted	O
PPSA	O
(	O
PPSA3	O
*	O
TMSA	O
/	O
1000	O
)	O

[	O
Zefirov	O
'	O
s	O
PC	O
]	O

ESP	O
-	O
FPSA	O
-	O
1	O
Fractional	O
PPSA	O
(	O
PPSA	O
-	O
1	O
/	O
TMSA	O
)	O

Thermodynamic	O

Translational	O
Entropy	O

Total	O
Entropy	O

Total	O
Enthalpy	O

Electrostatic	O

Max	O
partial	O
charge	O

Max	O
partial	O
charge	O
for	O
a	O
hydrogen	O
atom	O

Max	O
partial	O
charge	O
for	O
a	O
carbon	O
atom	O

Quantum	O
Chemical	O

Max	O
atomic	O
orbital	O
electronic	O
population	O

ESP	O
-	O
Max	O
net	O
atomic	O
charge	O

Avg	O
electroph	O
.	O
react	O
.	O
index	O
for	O
a	O
O	O
atom	O

Max	O
1	O
-	O
electron	O
react	O
.	O
index	O
for	O
a	O
C	O
atom	O

Max	O
SIGMA	O
-	O
PI	O
bond	O
order	O

ESP	O
-	O
Max	O
net	O
atomic	O
charge	O

ESP	O
-	O
Max	O
net	O
atomic	O
charge	O
for	O
a	O
N	O
atom	O

min	O
(#	O
HA	O
,	O
#	O
HD	O
)	O
[	O
Quantum	O
-	O
Chemical	O
PC	O
]	O

Min	O
e	O
-	O
n	O
attraction	O
for	O
a	O
C	O
-	O
C	O
bond	O

Min	O
e	O
-	O
n	O
attraction	O
for	O
a	O
C	O
-	O
H	O
bond	O

HOMO	O
-	O
1	O
energy	O
(	O
Molecular	O
orbital	O
related	O
)	O


LUMO	O
+	O
1	O
energy	O
(	O
Molecular	O
orbital	O
related	O
)	O

The	O
heuristic	O
method	O
(	O
HM	O
)	O
preselected	O
appropriate	O
molecular	O
descriptors	O
and	O
derived	O
the	O
linear	O
QSAR	O
model	O
based	O
on	O
them	O
.	O

Those	O
descriptors	O
that	O
exist	O
for	O
all	O
molecules	O
in	O
the	O
training	O
set	O
were	O
included	O
,	O
whereas	O
those	O
descriptors	O
whose	O
values	O
did	O
not	O
vary	O
throughout	O
the	O
training	O
set	O
were	O
excluded	O
from	O
the	O
regression	O
.	O

The	O
number	O
of	O
descriptors	O
in	O
the	O
final	O
QSAR	O
models	O
was	O
usually	O
less	O
than	O
one	O
third	O
of	O
the	O
number	O
of	O
molecules	O
in	O
the	O
data	O
set	O
[	O
60	O
].	O

HM	O
allows	O
us	O
to	O
obtain	O
the	O
best	O
QSAR	O
based	O
on	O
F	O
and	O
t	O
test	O
values	O
,	O
which	O
were	O
set	O
in	O
such	O
way	O
that	O
descriptors	O
having	O
more	O
than	O
0	O
.	O
99	O
and	O
less	O
than	O
0	O
.	O
8	O
correlations	O
were	O
excluded	O
as	O
they	O
may	O
generate	O
an	O
over	O
-	O
optimistic	O
regression	O
.	O

Molecular	O
descriptors	O
selected	O
by	O
the	O
heuristic	O
method	O
(	O
HM	O
)	O
in	O
CODESSA	O
were	O
used	O
as	O
inputs	O
to	O
perform	O
multiple	O
linear	O
regression	O
(	O
MLR	O
),	O
which	O
is	O
the	O
simplest	O
method	O
that	O
builds	O
a	O
single	O
regression	O
equation	O
for	O
a	O
given	O
data	O
set	O
.	O

For	O
each	O
regression	O
analysis	O
,	O
the	O
goodness	O
of	O
fit	O
was	O
evaluated	O
by	O
examining	O
the	O
number	O
of	O
molecules	O
(	O
N	O
),	O
coefficient	O
of	O
determination	O
(	O
r2	O
),	O
cross	O
-	O
validated	O
standard	O
error	O
(	O
Q2	O
)	O
and	O
value	O
of	O
the	O
F	O
-	O
statistic	O
(	O
F	O
).	O

The	O
Q2	O
value	O
obtained	O
through	O
the	O
leave	O
-	O
one	O
-	O
out	O
algorithm	O
(	O
LOO	O
)	O
cross	O
-	O
validation	O
procedure	O
reflects	O
the	O
stability	O
of	O
the	O
model	O
through	O
perturbation	O
of	O
the	O
regression	O
coefficients	O
with	O
the	O
acceptability	O
criterion	O
of	O
0	O
.	O
5	O
in	O
most	O
CoMFA	O
studies	O
[	O
61	O
].	O

The	O
model	O
validation	O
process	O

The	O
linear	O
QSAR	O
model	O
was	O
cross	O
validated	O
using	O
the	O
error	O
values	O
acquired	O
in	O
the	O
prediction	O
process	O
[	O
62	O
].	O

To	O
optimize	O
the	O
validation	O
outcomes	O
,	O
a	O
relationship	O
between	O
the	O
experimentally	O
obtained	O
values	O
and	O
computed	O
uptake	O
rates	O
from	O
the	O
test	O
set	O
was	O
established	O
using	O
the	O
heuristic	O
method	O
.	O

The	O
expected	O
values	O
for	O
each	O
compound	O
were	O
calculated	O
and	O
plotted	O
to	O
elucidate	O
their	O
correlations	O
with	O
the	O
experimental	O
values	O
.	O

Each	O
descriptor	O
was	O
assigned	O
a	O
number	O
through	O
the	O
web	O
based	O
random	O
number	O
generator	O
(	O
http	O
://	O
www	O
.	O
random	O
.	O
org	O
)	O
for	O
cross	O
validation	O
.	O

Individual	O
descriptors	O
were	O
sequentially	O
incorporated	O
into	O
the	O
regression	O
process	O
to	O
monitor	O
the	O
error	O
value	O
.	O

The	O
following	O
two	O
-	O
fold	O
cross	O
-	O
validation	O
scheme	O
was	O
implemented	O
.	O

1	O
.	O

The	O
experimental	O
data	O
(	O
25	O
)	O
were	O
divided	O
into	O
2	O
subsets	O
;	O
18	O
training	O
sets	O
and	O
7	O
test	O
sets	O
for	O
the	O
model	O
validation	O
.	O

2	O
.	O

The	O
data	O
from	O
the	O
selected	O
subsets	O
were	O
categorized	O
into	O
the	O
descriptors	O
listed	O
in	O
Table	O
5	O
.	O

3	O
.	O

The	O
odd	O
ratio	O
for	O
each	O
descriptor	O
was	O
calculated	O
to	O
find	O
the	O
most	O
potential	O
contributors	O
to	O
binding	O
property	O
with	O
defined	O
risk	O
weights	O
.	O

4	O
.	O

The	O
significance	O
of	O
the	O
final	O
regression	O
is	O
determined	O
by	O
comparing	O
prediction	O
Absolute	O
Relative	O
Errors	O
(	O
AREs	O
)	O
which	O
are	O
obtained	O
using	O
the	O
absolute	O
value	O
of	O
[(	O
Actual	O
Output	O
-	O
Predicted	O
Output	O
)/	O
Actual	O
Output	O
]	O
to	O
the	O
test	O
subset	O
.	O

An	O
estimated	O
p	O
value	O
less	O
than	O
0	O
.	O
05	O
was	O
considered	O
to	O
be	O
significant	O
for	O
the	O
consistency	O
of	O
the	O
model	O
.	O

The	O
model	O
with	O
the	O
lowest	O
prediction	O
error	O
generated	O
through	O
the	O
cross	O
validation	O
process	O
was	O
chosen	O
to	O
represent	O
the	O
best	O
outcome	O
for	O
each	O
BCRP	B-GP
polymorph	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
’	O
contribution	O

YL	O
designed	O
the	O
study	O
and	O
drafted	O
the	O
manuscript	O
.	O

SJ	O
performed	O
the	O
computational	O
modelling	O
process	O
and	O
statistical	O
analysis	O
.	O

GA	O
carried	O
out	O
the	O
cell	O
culture	O
,	O
drug	O
binding	O
and	O
immunoassay	O
.	O

CHL	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
coordination	O
and	O
helped	O
to	O
complete	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

